215 results
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
performed by the FDA or otherwise has jurisdiction over the safety, efficacy, approval, development, testing, labeling, manufacturing, storage, marketing
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
with GSK and the timeline expected in respect thereof;
the function, potential benefits, effectiveness and safety of camlipixant;
the accuracy of our … evaluating the efficacy, safety and tolerability of camlipixant in RCC. Both trials are running concurrently, and each will recruit approximately 675 adult
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
development of its P2X3 receptor pipeline.
BELLUS Health reported positive results from its Phase 1 clinical trial investigating the safety … bioavailability to the twice-daily Immediate Release (“IR”) formulation. In addition, the ER formulation was well tolerated, with safety data observed
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
) quality, safety and accreditation standards and requirements of all applicable Governmental Bodies, (x) all Laws pursuant to which permits relating … been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health
6-K
EX-99.1
BLU
Bellus Health Inc
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reported
Additional … formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reported
6-K
EX-99.1
p5478a9o8fyt08vc
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
jd0 q52tiqsyc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
skm syinee
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
3oe5lb4aqj7358 gr
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
k8s0zg8h90c95
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
F-10
jkz3saajl1gr2gbq
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.2
3sr8rz
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
SUPPL
siui1 c15f
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.2
w2smzdpkq1cwdp2t
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
ozfp4lav6e2spj
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.2
3oozhbf3vzzovc3mp
13 Jul 22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:25pm
6-K
EX-99.2
zhobsc5hbjtz
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
i0gm5y86v6in45qjr
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
wrv6eaudw4penalybfm
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm
6-K
EX-99.2
kwrisk1x4 pzsu5
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm